Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion pexelizumab fails second PRIMO study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Alexion's terminal complement inhibitor pexelizumab fails to show statistical significance in the firm's second coronary artery bypass graft trial, PRIMO-CABG2. Alexion is assessing the implications of the results on its APEX-AMI study of the biologic in acute myocardial infarction. When pexelizumab failed the first PRIMO (Pexelizumab for Reduction in Infarction & Mortality) study in August 2003, Alexion said the results could be used to support an AMI indication (Pharmaceutical Approvals Monthly September 2003, p. 21). The APEX study has enrolled 3,000 patients, according to the firm...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel